RecruitingNot Applicable

Secondary Sclerosis Cholangitis Prospective

Austria380 participantsStarted 2018-07-20

Plain-language summary

SC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. Gut microbiome composition, gut permeability, bacterial translocation, inflammation and/or genetic variants contribute to the pathogenesis The aim of this project is to study gut microbiome composition, gut permeability, bacterial translocation, inflammation, bile acid composition and genetic polymorphisms by conducting a prospective cohort study in patients with a high risk to develop SC-CIP.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study OR "surrogate consent" by the institutional review board. * Age above 18 years * Mechanical ventilation or extracorporeal membrane oxygenation \>/= 5 days Exclusion Criteria: * Primary or secondary sclerosing cholangitis diagnosed before current ICU admission

What they're measuring

Incidence of SC-CIP in patients at risk

Timeframe: during hospital stay, on average 4 weeks

Trial details

NCT IDNCT03566797

SponsorMedical University of Graz

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Secondary Sclerosis Cholangitis in Critically Ill Patients trials